Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Switzerland-based antibody therapy developer NovaGo Therapeutics, a spinout of University of Zurich, completed a CHF10m ($10m) series A round on Monday featuring biopharmaceutical company Neurimmune, which invested through a strategic partnership agreement. The round was led by venture capital fund Pureos Bioventures and the funding will be used to advance NovaGo’s regenerative medicines toward clinical trials.
Telecommunications and internet group SoftBank agreed on Monday to invest $10m in Sweden-based solar cell manufacturer Exeger Operations through a strategic partnership agreement, in…
